Quinolones, are a class of widely used and popular powerful antibiotics with broad coverage. RSI investigators, Mohamed Taher, Franco Momoli, Donald Mattison and Daniel Krewski, recently published a series of three papers on investigating the risk of acute liver failure (ALF) following systemic administration of quinolones, based on a synthesis of evidence from available clinical trials, the US FDA Adverse Event Reporting System (FAERS), and a large US database of electronic health records (EHR).
Although clinical trials provided little evidence of an increased risk, there were reports in FAERS of quinolone-linked ALF cases. Although the primary EHR analysis did not reveal an overall association between quinolones as a class and ALF risk, a possible risk was identified among those with no or few comorbidities, those ≤ 60 years of age, women, men, African Americans, and Caucasians.
The authors noted that elevated risks seen in some subgroups warrant further investigation.
Posted in RSI News
More RSI News
RSI launches Global Risk Census
Risk Sciences International has launched The Global Risk Census. The goal of the Census is to provide insights into important risks that need to be…
Read News ItemUS FDA FAERS and quinolones
Some case reports on Quinolones, a potent and globally popular group of antibiotics that are used to treat a wide range of infections, have raised…
Read News ItemAdvancing Toxicity Testing webinar
The Center for Alternatives to Animal Testing and the Animal-Free Safety Assessment recently held their annual meeting on advancing toxicity testing in the 21st century…
Read News ItemUSC appoints Dr. Mattison distinguished professor
Dr. Donald Mattison, RSI’s Senior Vice-President and Chief Medical Officer, has accepted an appointment as a University of South Carolina Health Sciences Distinguished Professor in the in…
Read News Item